Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Roche is buying Genmark Diagnostics for $1.8 billion or €1.5 billion, and this was revealed on Monday, March 15. The price is for the full acquisition of the US-based molecular diagnostic tests maker.
The numbers in Roche’s newest investment
Roche’s price offer is equivalent to the price of $24.05 per share in an all-cash deal. This also showed a premium of 43% on GenMark’s closing stock on Feb. 10, just before the speculations about Roche’s plans to purchase GenMark made rounds, as per CNBC.
The Swiss pharmaceuticals manufacturer company decided to buy the leading provider of multiplex molecular diagnostic solutions so it can expand the business and make its presence in the diagnostics sector.
“Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases,” Thomas Schinecker, Roche’s chief executive officer, said via press release.
It was added that the acquisition that was approved by the respective board of directors of Roche and GenMark Diagnostics is expected to be completed within the second quarter of 2021. Once the negotiations are done, the latter’s main operations will not be moved but will continue in its current office location in Carlsbad, California.
The setup in the merger deal
The terms in the merger agreement were partly disclosed, and one clause states that Roche will immediately and directly initiate a tender offer to purchase all outstanding stocks of GenMark’s shares.
At any rate, GenMark’s portfolio will complement and further enhance Roche’s molecular diagnostics portfolio. It is also expected that the Swiss company will widen its global network reach when it starts to distribute GenMark’s items and products.
“As a part of Roche, we can accelerate our mission to enable rapid diagnosis of infectious disease to improve patient outcomes,” CEO of GenMark Diagnostics, Scott Mendel, said. “Together with Roche’s diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world.”
Finally, Mendel added that GenMark is thrilled to become part of the globally known Roche. He is confident that they made the right decision to move forward with the Swiss firm.
